Ra Capital Management, Llc's Trading History
| WVEWave Life Sciences | Oct 07, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $96.98M | |
| VORVor Biopharma | Oct 05, 2026 | Ten Percent Owner | Uninformative Buy | 6.40K | $88.64M | |
| CLYMClimb Bio | Sep 30, 2026 | Director, Ten Percent Owner | Uninformative Buy | 195.10K | $103.83M | |
| SIONSionna Therapeutics, Inc. | Sep 21, 2026 | Director, Ten Percent Owner | Informative Sell | 21.84M | $24.99M | |
| SEPNSepterna, Inc. | Aug 14, 2026 | Director, Ten Percent Owner | Informative Sell | 63.45M | $31.92M | |
| ARTVArtiva Biotherapeutics, Inc. | Jul 31, 2026 | Director, Ten Percent Owner | Informative Buy | 455.73K | $77.47M | |
| IKTInhibikase Therapeutics | Jul 31, 2026 | Ten Percent Owner | Uninformative Sell | ― | $10.80M | |
| PBLSParabilis Medicines, Inc. | Jul 22, 2026 | Director, Ten Percent Owner | Informative Buy | 6.92M | $826.32M | |
| FRNMFreenome Inc | Jul 22, 2026 | Director, Ten Percent Owner | Uninformative Buy | 52.55M | $15.54M | |
| HOWLWerewolf Therapeutics | Jun 22, 2026 | Ten Percent Owner | Informative Sell | 145.92K | $299.47K | |
| COAGHemab Therapeutics Holdings, Inc. | Jun 17, 2026 | Ten Percent Owner | Informative Buy | 1.69M | $323.67M | |
| JANXJanux Therapeutics Inc | Jun 12, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $195.69M | |
| ABOSAcumen Pharmaceuticals | Jun 05, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $4.42M | |
| ACRVAcrivon Therapeutics, Inc. | May 20, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $20.32M | |
| ACETAdicet Bio | Apr 29, 2026 | Ten Percent Owner | Uninformative Sell | ― | $3.19M | |
| PRLDPrelude Therapeutics | Apr 28, 2026 | Ten Percent Owner | Uninformative Sell | ― | $25.13M | |
| MLYSMineralys Therapeutics, Inc. | Mar 31, 2026 | Director | Informative Buy | 8.76M | $139.85M | |
| BCAXBicara Therapeutics Inc. | Mar 02, 2026 | Director, Ten Percent Owner | Informative Buy | 4.80M | $66.25M | |
| EVMNEvommune, Inc. | Feb 17, 2026 | Director | Uninformative Buy | 1.00M | $23.52M | |
| SGPSpyGlass Pharma | Feb 11, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $66.24M | |
| CDTXCidara Therapeutics | Jan 09, 2026 | ― | Uninformative Buy | 284.87M | $0.00 | |
| FULCFulcrum Therapeutics | Dec 10, 2025 | Ten Percent Owner | Informative Sell | 58.38M | $22.46M | |
| PEPGPepGen Inc. | Sep 30, 2025 | Director, Ten Percent Owner | Informative Buy | 30.00M | $47.35M | |
| TYRATyra Bioscience | Jun 16, 2025 | Director, Ten Percent Owner | Informative Buy | 1.66M | $257.03M | |
| JBIOJade Biosciences | Apr 30, 2025 | Ten Percent Owner | Uninformative Buy | ― | $18.63M | |
| ETNB89bio | Feb 03, 2025 | ― | Informative Buy | 50.00M | $295.16M | |
| FDMT4D Molecular Therapeutics | Dec 10, 2024 | Ten Percent Owner | Uninformative Sell | ― | $54.30M | |
| ANTXAN2 Therapeutics, Inc. | Aug 13, 2024 | Ten Percent Owner | Informative Sell | 3.81M | $1.36M | |
| ITOSiTeos Therapeutics | May 14, 2024 | ― | Uninformative Sell | ― | $35.70M | |
| BOLDBoundless Bio Inc. | Apr 04, 2024 | Ten Percent Owner | Uninformative Buy | ― | $730.73K | |
| NKTXNkarta | Mar 29, 2024 | Director, Ten Percent Owner | Informative Buy | 30.00M | $16.86M | |
| SPRYARS Pharmaceuticals | Mar 27, 2024 | Director, Ten Percent Owner | Informative Buy | 13.29M | $36.71M | |
| LENZLENZ Therapeutics | Mar 25, 2024 | Director, Ten Percent Owner | Uninformative Buy | ― | $4.24M | |
| ICVXIcosavax | Feb 20, 2024 | ― | Uninformative Sell | ― | $0.00 | |
| SLDBSolid Biosciences | Jan 12, 2024 | Ten Percent Owner | Informative Buy | 5.00M | $26.67M | |
| ~DICEDice Therapeutics | Aug 09, 2023 | ― | Uninformative Sell | ― | $0.00 | |
| BDTXBlack Diamond Therapeutics | Jul 07, 2023 | Director | Informative Buy | 4.68M | $6.28M | |
| STSASatsuma Pharmaceuticals | Jun 12, 2023 | ― | Uninformative Sell | ― | $0.00 | |
| ELVNEnliven Therapeutics | Feb 27, 2023 | Former 10% owner | Uninformative Buy | ― | $93.92M | |
| FMTXForma Therapeutics Holdings | Oct 14, 2022 | ― | Uninformative Sell | ― | $0.00 | |
| KALAKALA BIO | May 26, 2022 | Ten Percent Owner | Informative Sell | 362.05K | $1.16M | |
| CTKBCytek Biosciences | Mar 16, 2022 | Director, Ten Percent Owner | Uninformative Buy | 7.19M | $82.03M | |
| PNTPOINT Biopharma Global | Jun 30, 2021 | ― | Informative Buy | 2.09M | $13.73M | |
| SCPHscPharmaceuticals | Mar 16, 2021 | ― | Informative Sell | 1.06M | $15.46M | |
| PHATPhathom Pharmaceuticals | Mar 15, 2021 | Ten Percent Owner | Informative Sell | 31.06M | $17.88M | |
| ITRMFIterum Therapeutics | Feb 08, 2021 | Ten Percent Owner | Uninformative Buy | ― | $361.20K | |
| RYTMRhythm Pharmaceuticals | Dec 04, 2020 | Former 10% Owner | Informative Sell | 7.03M | $403.68M | |
| ORTXOrchard Therapeutics | Nov 06, 2020 | ― | Informative Buy | 3.56M | $165.01M | |
| PCVXVaxcyte | Oct 01, 2020 | Ten Percent Owner | Informative Sell | 11.24M | $327.76M | |
| PMVPPMV Pharmaceuticals | Sep 29, 2020 | Ten Percent Owner | Uninformative Buy | ― | $2.24M | |
| DYNDyne Therapeutics | Sep 23, 2020 | Ten Percent Owner | Uninformative Buy | ― | $46.82M | |
| TGTXTG Therapeutics | Sep 11, 2020 | Ten Percent Owner | Informative Sell | 4.09M | $772.70M | |
| ~INBXInhibrx | Aug 24, 2020 | ― | Uninformative Buy | ― | $72.62M | |
| INZYInozyme Pharma | Jul 28, 2020 | ― | Uninformative Buy | ― | $8.01M | |
| PANDPandion Therapeutics | Jul 22, 2020 | ― | Uninformative Buy | ― | $106.29M | |
| AKUSAKOUOS | Jul 02, 2020 | ― | Uninformative Buy | ― | $30.32M | |
| VSTMVerastem | Jun 29, 2020 | Ten Percent Owner | Informative Sell | 2.22M | $157.38M | |
| RARXRa Pharmaceuticals | Apr 03, 2020 | ― | Uninformative Sell | 233.20M | $0.00 | |
| ~~THORSynthorx | Jan 24, 2020 | ― | Uninformative Sell | 661.27M | $0.00 | |
| ~THORThoratec Corp | Dec 13, 2018 | ― | Uninformative Buy | ― | $617.51M | |
| ARVNArvinas Holding Company | Oct 03, 2018 | Former 10% Owner | Uninformative Buy | ― | $24.67M | |
| EIDXEidos Therapeutics | Jun 22, 2018 | ― | Uninformative Buy | ― | $264.30M | |
| KALVKalVista Pharmaceuticals | Oct 16, 2017 | ― | Informative Buy | 7.22M | $15.96M | |
| ACRSAclaris Therapeutics | Sep 19, 2016 | Ten Percent Owner | Informative Sell | 12.71M | $8.35M | |
| SGMOQSangamo Therapeutics | Feb 18, 2015 | Former 10% Owner | Informative Buy | ― | $639.44K | |
| ~ACHNAchillion Pharmaceuticals | Jan 20, 2015 | ― | Informative Buy | 7.83M | $32.56M | |
| DRNADicerna Pharma | Feb 05, 2014 | ― | Informative Buy | 15.00M | $193.93M | |
| DSCIDerma Sciences | Jan 13, 2014 | ― | Informative Sell | 3.55M | $11.86M | |
| BSTCBiospecifics Technologies | Feb 26, 2010 | ― | Informative Sell | 288.30K | $55.46M | |
| ARDMQAradigm | ― | ― | ― | $49.74K | ||
| CRISCuris | ― | Ten Percent Owner | ― | $3.75M | ||
| SQNMSequenom | ― | ― | ― | $27.21M |
You May Also Like
Ra Capital Management, Llc insider profile FAQ
What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 33%.
What is the average return per transaction made by Ra Capital Management, Llc?
The average return per transaction made by Ra Capital Management, Llc is -1.90%.
What stocks does Ra Capital Management, Llc hold?
Ra Capital Management, Llc holds: WVE, ~ACHN, ~THOR, VSTM, TGTX, KALV, CDTX, ACRS, RARX, KALA, RYTM, SCPH, ACET, SLDB, ITRMF, EIDX, ARVN, ORTX, ~~THOR, FULC, STSA, PHAT, ETNB, BDTX, ELVN, PCVX, FMTX, AKUS, NKTX, PNT, PAND, INZY, ITOS, ~INBX, DYN, PMVP, PRLD, IKT, SPRY, FDMT, VOR, HOWL, JANX, LENZ, ABOS, JBIO, CTKB, ICVX, CLYM, ~DICE, TYRA, ANTX, PEPG, ACRV, MLYS, BOLD, FRNM, ARTV, BCAX, SEPN, SION, EVMN, SGP, COAG, PBLS, SGMOQ, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
What was Ra Capital Management, Llc's most profitable transaction?
Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
What is Ra Capital Management, Llc's role in Wave Life Sciences?
Ra Capital Management, Llc's role in Wave Life Sciences is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.